Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
US10053485B2 · kind B2 · utility
2Cited by
9References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 22, 2016 |
| Grant date | Aug 21, 2018 |
| Priority date | — |
| Expiry date | Mar 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J71/001
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.